Merrimack Pharmaceuticals' (MACK) MM-121 misses its PFS primary endpoint in a Phase 2 trial evaluating the treatment in combination with paclitaxel versus paclitaxel alone in patients with platinum-resistant or platinum-refractory advanced ovarian cancers.
Hazard Ratio was 1.
The company says "ongoing analysis of a pre-specified set of biomarkers mechanistically linked to ErbB3 signaling identified a potential subpopulation of patients benefiting from MM-121 treatment in combination with paclitaxel."
In the group receiving the combination therapy, there was "an overall increase in all grades of gastrointestinal toxicities." (PR)
MACK -12% premarket.